glp-1 for lipedema How Medications Can Support Patients GLP-1 Medications and Lipedema |

Here, we present a ligand-based proximity labeling approach to interrogate the native cell membrane interactome for the GLP-1 receptor after agonist simulation

American College of Cardiology

The STEP 1 trial showed 14.9% weight loss at 2.4 mg/week over 68 weeks (Wilding et al., 2021)

Check Your Eligibility Free Consultation (Prospective Patients) Starting July 1, 2026 , Medicare Part D covers Wegovy, Zepbound, and Foundayo for weight loss through the new GLP-1 Bridge program

PlexusDx offers the Precision Peptide Genetic Test, which analyzes 14 metabolic pathways and 49 peptides to show how your unique genetics influence your response to semaglutide, tirzepatide, and other weight-loss compounds